Sirtuins in neurodegenerative diseases: A biological-chemical perspective

Neurodegenerative Diseases

Volumn 9, Issue 1, 2011, Pages 1-10

  Raghavan, Aparna ^a   Shah, Zahoor A ^a  

^a UNIVERSITY OF TOLEDO   (United States)

Author keywords

ADP ribosylation; Deacetylation; Neurodegenerative diseases; Sirtuins

Indexed keywords

SIRTUIN;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BINDING SITE; BRAIN ISCHEMIA; CALORIC RESTRICTION; CATALYSIS; DEGENERATIVE DISEASE; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYME STRUCTURE; HUMAN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; REVIEW;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN ISCHEMIA; GROUP III HISTONE DEACETYLASES; HUMANS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PROTEIN STRUCTURE, TERTIARY; SIRTUINS; SUBSTRATE SPECIFICITY;

EID: 82455212997     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000329724     Document Type: Review

References (58)

1. Shoba B, Lwin ZM, Ling LS, Bay BH, Yip GW, Dinesh S: Function of sirtuins in biological tissues. Anat Rec 2009; 292: 536-543.
2. Shore D, Squire M, Nasmyth KA: Characterization of two genes required for the position - effect control of yeast mating-type genes. EMBO J 1984; 3: 2817-2823.
3. Kaeberlein M, McVey M, Guarente L: The sir2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev 1999; 13: 2570-2580. (Pubitemid 29489648)
4. Liszt G, Ford E, Kurtev M, Guarente L: Mouse SIR2 homolog SIRT6 is a nuclear ADP-ribosyltransferase. J Biol Chem 2005; 280: 21313-21320. (Pubitemid 40805693)
5. Landry J, Sutton A, Tafrov ST, Heller RC, Stebbins J, Pillus L, Sternglanz R: The silencing protein SIR2 and its homologs are NADdependent protein deacetylases. Proc Natl Acad Sci USA 2000; 97: 5807-5811. (Pubitemid 30367480)
6. Michan S, Sinclair D: Sirtuins in mammals: insights into their biological function. Biochem J 2007; 404: 1-13. (Pubitemid 46788079)
7. Dali-Youcef N, Lagouge M, Froelich S, Koehl C, Schoonjans K, Auwerx J: Sirtuins: the 'magnificent seven', function, metabolism and longevity. Ann Med 2007; 39: 335-345.
8. Lavu S, Boss O, Elliott PJ, Lambert PD: Sirtuins - novel therapeutic targets to treat ageassociated diseases. Nat Rev Drug Discov 2008; 7: 841-853.
9. Imai S, Armstrong CM, Kaeberlein M, Guarente L: Transcriptional silencing and longevity protein sir2 is an NAD-dependent histone deacetylase. Nature 2000; 403: 795-800. (Pubitemid 30111843)
10. Vaquero A, Scher M, Lee D, Erdjument-Bromage H, Tempst P, Reinberg D: Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell 2004; 16: 93-105. (Pubitemid 39330155)
11. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA: hSIR22(SIRT1) functions as an NADdependent p53 deacetylase. Cell 2001; 107: 149-159. (Pubitemid 33035942)
12. Yang Y, Hou H, Haller EM, Nicosia SV, Bai W: Suppression of foxo1 activity by fhl2 through SIRT1-mediated deacetylation. EMBO J 2005; 24: 1021-1032. (Pubitemid 40470150)
13. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, Bultsma Y, McBurney M, Guarente L: Mammalian SIRT1 represses forkhead transcription factors. Cell 2004; 116: 551-563. (Pubitemid 38264432)
14. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, Greenberg ME: Stress-dependent regulation of foxo transcription factors by the SIRT1 deacetylase. Science 2004; 303: 2011-2015. (Pubitemid 38393275)
15. Nemoto S, Fergusson MM, Finkel T: SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J Biol Chem 2005; 280: 16456-16460. (Pubitemid 40616776)
16. Haigis MC, Sinclair DA: Mammalian sirtuins: Biological insights and disease relevance. Annu Rev Pathol Mech Dis 2010; 5: 253-295.
17. Wang J, Fivecoat H, Ho L, Pan Y, Ling E, Pasinetti GM: The role of SIRT1: at the crossroad between promotion of longevity and protection against Alzheimer's disease neuropathology. Biochim Biophys Acta 2010; 1804: 1690-1694.
18. Hisahara S, Chiba S, Matsumoto H, Horio Y: Transcriptional regulation of neuronal genes and its effect on neural functions: Nad-dependent histone deacetylase SIRT1 (SIR2alpha). J Pharmacol Sci 2005; 98: 200-204. (Pubitemid 41296398)
19. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P: Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005; 434: 113-118. (Pubitemid 40349395)
20. Liu D, Gharavi R, Pitta M, Gleichmann M, Mattson MP: Nicotinamide prevents NAD + depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD + consumption by sirt1 may endanger energetically compromised neurons. Neuromolecular Med 2009; 11: 28-42.
21. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW, Shulman GI: Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003; 300: 1140-1142. (Pubitemid 36583097)
22. Singh KK: Mitochondrial dysfunction is a common phenotype in aging and cancer. Ann NY Acad Sci 2004; 1019: 260-264. (Pubitemid 38951316)
23. Luchsinger JA, Tang MX, Shea S, Mayeux R: Caloric intake and the risk of Alzheimer disease. Arch Neurol 2002; 59: 1258-1263. (Pubitemid 34856378)
24. Hendrie HC, Ogunniyi A, Hall KS, Baiyewu O, Unverzagt FW, Gureje O, Gao S, Evans RM, Ogunseyinde AO, Adeyinka AO, Musick B, Hui SL: Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA 2001; 285: 739-747. (Pubitemid 32167232)
25. Mattson MP: Will caloric restriction and folate protect against AD and PD? Neurology 2003; 60: 690-695. (Pubitemid 36246090)
26. Wang J, Ho L, Qin W, Rocher AB, Seror I, Humala N, Maniar K, Dolios G, Wang R, Hof PR, Pasinetti GM: Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease. FASEB J 2005; 19: 659-661. (Pubitemid 40471277)
27. Patel NV, Gordon MN, Connor KE, Good RA, Engelman RW, Mason J, Morgan DG, Morgan TE, Finch CE: Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiol Aging 2005; 26: 995-1000. (Pubitemid 40312661)
28. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S, Mucke L, Gan L: SIRT1 protects against microglia-dependent amyloidbeta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 2005; 280: 40364-40374. (Pubitemid 41779174)
29. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, Delalle I, Baur JA, Sui G, Armour SM, Puigserver P, Sinclair DA, Tsai LH: SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 2007; 26: 3169-3179. (Pubitemid 47057498)
30. Green KN, Steffan JS, Martinez-Coria H, Sun X, Schreiber SS, Thompson LM, LaFerla FM: Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-Phosphotau. J Neurosci 2008; 28: 11500-11510.
31. Outeiro TF, Marques O, Kazantsev A: Therapeutic role of sirtuins in neurodegenerative disease. Biochim Biophys Acta 2008; 1782: 363-369.
32. Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet JC, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman BT, Kazantsev AG: Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007; 317: 516-519. (Pubitemid 47196116)
33. Albani D, Polito L, Batelli S, De Mauro S, Fracasso C, Martelli G, Colombo L, Manzoni C, Salmona M, Caccia S, Negro A, Forloni G: The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide. J Neurochem 2009; 110: 1445-1456.
34. Okawara M, Katsuki H, Kurimoto E, Shibata H, Kume T, Akaike A: Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults. Biochem Pharmacol 2007; 73: 550-560. (Pubitemid 46038859)
35. Raval AP, Dave KR, Perez-Pinzon MA: Resveratrol mimics ischemic preconditioning in the brain. J Cereb Blood Flow Metab 2006; 26: 1141-1147. (Pubitemid 44268176)
36. Della-Morte D, Dave KR, DeFazio RA, Bao YC, Raval AP, Perez-Pinzon MA: Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway. Neuroscience 2009; 159: 993-1002.
37. Wang T, Gu J, Wu PF, Wang F, Xiong Z, Yang YJ, Wu WN, Dong LD, Chen JG: Protection by tetrahydroxystilbene glucoside against cerebral ischemia: involvement of JNK, SIRT1, and NF-kappaB pathways and inhibition of intracellular ROS/RNS generation. Free Radic Biol Med 2009; 47: 229-240.
38. Smith BC, Hallows WC, Denu JM: Mechanisms and molecular probes of sirtuins. Chem Biol 2008; 15: 1002-1013.
39. Kowieski TM, Lee S, Denu JM: Acetylationdependent ADP-ribosylation by Trypanosoma brucei SIR2. J Biol Chem 2008; 283: 5317-5326.
40. Smith BC, Denu JM: SIR2 protein deacetylases: evidence for chemical intermediates and functions of a conserved histidine. Biochemistry 2006; 45: 272-282. (Pubitemid 43054104)
41. Sauve AA, Schramm VL: SIR2 regulation by nicotinamide results from switching between base exchange and deacetylation chemistry. Biochemistry 2003; 42: 9249-9256. (Pubitemid 36959231)
42. Chen Y, Sprung R, Tang Y, Ball H, Sangras B, Kim SC, Falck JR, Peng J, Gu W, Zhao Y: Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol Cell Proteomics 2007; 6: 812-819. (Pubitemid 46831933)
43. Cheng Z, Tang Y, Chen Y, Kim S, Liu H, Li SS, Gu W, Zhao Y: Molecular characterization of propionyllysines in non-histone proteins. Mol Cell Proteomics 2009; 8: 45-52.
44. Sanders BD, Jackson B, Marmorstein R: Structural basis for sirtuin function: what we know and what we don't. Biochim Biophys Acta 2010; 1804: 1604-1616.
45. Min J, Landry J, Sternglanz R, Xu RM: Crystal structure of a SIR2 homolog-NAD complex. Cell 2001; 105: 269-279. (Pubitemid 32429516)
46. Finnin MS, Donigian JR, Pavletich NP: Structure of the histone deacetylase SIR2. Nat Struct Biol 2001; 8: 621-625.
47. Zhao K, Harshaw R, Chai X, Marmorstein R: Structural basis for nicotinamide cleavage and ADP-ribose transfer by NAD(+)-dependent SIR2 histone/protein deacetylases. Proc Natl Acad Sci USA 2004; 101: 8563-8568. (Pubitemid 38745810)
48. Hawse WF, Hoff KG, Fatkins DG, Daines A, Zubkova OV, Schramm VL, Zheng W, Wolberger C: Structural insights into intermediate steps in the SIR2 deacetylation reaction. Structure 2008; 16: 1368-1377.
49. Avalos JL, Celic I, Muhammad S, Cosgrove MS, Boeke JD, Wolberger C: Structure of a SIR2 enzyme bound to an acetylated p53 peptide. Mol Cell 2002; 10: 523-535. (Pubitemid 35291068)
50. Cosgrove MS, Bever K, Avalos JL, Muhammad S, Zhang X, Wolberger C: The structural basis of sirtuin substrate affinity. Biochemistry 2006; 45: 7511-7521. (Pubitemid 43894945)
51. Garske AL, Denu JM: Sirt1 top 40 hits: use of one-bead, one-compound acetyl-peptide libraries and quantum dots to probe deacetylase specificity. Biochemistry 2006; 45: 94-101. (Pubitemid 43054086)
52. Zhao K, Chai X, Marmorstein R: Structure and substrate binding properties of cobB, a SIR2 homolog protein deacetylase from Escherichia coli . J Mol Biol 2004; 337: 731-741. (Pubitemid 38326887)
53. Borra MT, Langer MR, Slama JT, Denu JM: Substrate specificity and kinetic mechanism of the sir2 family of NAD + -dependent histone/ protein deacetylases. Biochemistry 2004; 43: 9877-9887. (Pubitemid 38993837)
54. Blander G, Guarente L: The SIR2 family of protein deacetylases. Annu Rev Biochem 2004; 73: 417-435. (Pubitemid 39050375)
55. Asaba T, Suzuki T, Ueda R, Tsumoto H, Nakagawa H, Miyata N: Inhibition of human sirtuins by in situ generation of an acetylated lysine-ADP-ribose conjugate. J Am Chem Soc 2009; 131: 6989-6996.
56. Jamonnak N, Hirsch BM, Pang Y, Zheng W: Substrate specificity of SIRT1-catalyzed lysine Nepsilon-deacetylation reaction probed with the side chain modified Nepsilon-acetyl- lysine analogs. Bioorg Chem 2010; 38: 17-25.
57. Blum CA, Ellis JL, Loh C, PY NG, Perni RB, Stein RL: SIRT1 modulation as a novel approach to the treatment of diseases of aging. J Med Chem 2011; 54: 417-432.
58. Sauve AA: Pharmaceutical strategies for activating sirtuins. Curr Pharm 2009; 15: 45-56.